We are live on
!
Find out more
OM
Opaleye Management Portfolio holdings
AUM
$758M
1-Year Est. Return
124.8%
This Fund
S&P 500
This Quarter
Est. Return
+16.07%
1 Year Est. Return
+124.8%
3 Year Est. Return
+486.05%
5 Year Est. Return
+742.19%
10 Year Est. Return
+62,231.09%
AUM
$758M
AUM Growth
+$50.6M
(+7.1%)
Cap. Flow
+$32.3M
Cap. Flow
% of AUM
4.26%
Top 10 Holdings %
Top 10 Hldgs %
65.47%
Holding
64
New
21
Increased
16
Reduced
8
Closed
9
Top Buys
| 1 |
Rezolute
RZLT
|
+$42.2M |
| 2 |
CBIO
Crescent Biopharma
CBIO
|
+$15M |
| 3 |
ACOG
Alpha Cognition
ACOG
|
+$12.4M |
| 4 |
Sol-Gel Technologies
SLGL
|
+$9.61M |
| 5 |
UroGen Pharma
URGN
|
+$5.82M |
Top Sells
| 1 |
Immunome
IMNM
|
+$37.3M |
| 2 |
Rhythm Pharmaceuticals
RYTM
|
+$14M |
| 3 |
Codexis
CDXS
|
+$12.2M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$11.3M |
| 5 |
Larimar Therapeutics
LRMR
|
+$10.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Karyopharm Therapeutics
KPTI
$226M
| $6.84M | 0.9% |
+930,000
| New | +$5.69M |
|
|
JBIO
27
Jade Biosciences
JBIO
$1.31B
| $6.6M | 0.87% |
+427,608
| New | +$5.02M |
|
|
28
UroGen Pharma
URGN
$1.93B
| $6.29M | 0.83% |
+268,423
| New | +$5.82M |
|
|
ALMS
29
Alumis Inc
ALMS
$3.48B
| $5.22M | 0.69% |
535,000
-130,000
| -20% | -$908K |
|
30
Perspective Therapeutics
CATX
$342M
| $4.99M | 0.66% |
+1,184,500
| New | +$3.38M |
|
31
Voyager Therapeutics
VYGR
$194M
| $4.7M | 0.62% |
+1,196,904
| New | +$5.29M |
|
32
Relmada Therapeutics
RLMD
$669M
| $4.52M | 0.6% |
+935,000
| New | +$3.13M |
|
|
TECX
33
Tectonic Therapeutic
TECX
$662M
| $4.48M | 0.59% |
+214,747
| New | +$3.99M |
|
34
Protalix BioTherapeutics
PLX
$189M
| $4.46M | 0.59% |
2,478,176
-102,380
| -4% | -$209K |
|
35
Trevi Therapeutics
TRVI
$2.52B
| $4.32M | 0.57% |
345,100
-44,900
| -12% | -$519K |
|
36
Fortress Biotech
FBIO
$121M
| $3.99M | 0.53% |
+1,090,000
| New | +$3.11M |
|
37
Rocket Pharmaceuticals
RCKT
$401M
| $3.35M | 0.44% |
+955,000
| New | +$3.27M |
|
38
MeiraGTx Holdings
MGTX
$1.17B
| $3.11M | 0.41% |
+390,844
| New | +$3.25M |
|
39
Rigel Pharmaceuticals
RIGL
$757M
| $3M | 0.4% |
70,000
+32,213
| +85% | +$1.21M |
|
40
Zymeworks
ZYME
$1.83B
| $2.87M | 0.38% |
108,929
+8,929
| +9% | +$195K |
|
|
ASRT
41
DELISTED
Assertio
ASRT
| $2.58M | 0.34% |
+285,000
| New | +$3.33M |
|
|
VTYX
42
DELISTED
Ventyx Biosciences
VTYX
| $2.27M | 0.3% |
+251,932
| New | +$1.88M |
|
|
IRD
43
Opus Genetics
IRD
$299M
| $2.25M | 0.3% |
1,120,000
+20,000
| +2% | +$40.6K |
|
44
Sutro Biopharma
STRO
$438M
| $2.21M | 0.29% |
+190,671
| New | +$1.81M |
|
45
Cabaletta Bio
CABA
$442M
| $1.97M | 0.26% |
900,000
+91,118
| +11% | +$226K |
|
46
Zentalis Pharmaceuticals
ZNTL
$330M
| $1.89M | 0.25% |
1,400,906
+1,084,356
| +343% | +$1.58M |
|
|
GBIO
47
DELISTED
Generation Bio
GBIO
| $1.76M | 0.23% |
+310,000
| New | +$1.75M |
|
48
BridgeBio Pharma
BBIO
$16.5B
| $1.4M | 0.18% |
+18,319
| New | +$1.2M |
|
49
Enanta Pharmaceuticals
ENTA
$391M
| $1.18M | 0.16% |
+75,000
| New | +$953K |
|
50
Q32 Bio
QTTB
$308M
| $708K | 0.09% |
+213,363
| New | +$603K |
|
Similar funds
WCFA
SIG
GWM
IAS
TVAMP
RFM
MWA
CFS